Burns : journal of the International Society for Burn Injuries · 2026
Persistent immune dysregulation consistent with chronic low-grade inflammation in paediatric burn survivors.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Langley Donna, Holland Andrew J A, Stefanutti Giorgio, Kimble Roy M, Kenna Tony, Cuttle Leila
Аннотация
OBJECTIVES: To characterise long-term immune dysregulation and persistent inflammatory signalling in paediatric burn survivors with hypertrophic scarring.
METHODS: Peripheral blood mononuclear cells and plasma were analysed from 20 paediatric participants: 10 burn survivors with hypertrophic scarring (median 4.1 years post-injury) and 10 age- and sex-matched healthy controls. Multiparameter flow cytometry, multiplex cytokine analysis, and quantitative reverse-transcription polymerase chain reaction (qRT-PCR) were used to assess immune cell phenotypes, inflammatory mediators, and inflammatory gene expression.
RESULTS: Overall proportions of major immune cell subsets were comparable between groups. However, burn survivors with hypertrophic scarring demonstrated increased CD4⁺TNFα⁺ cells, Th17 cells, CCR6⁺ natural killer T-like cells, IL-23⁺ natural killer cells, and IL-23-expressing macrophage populations (all P < 0.05). Regulatory T cells (Tregs) and CCR4⁺CCR6⁺ double-positive Tregs were also increased (P < 0.05). Plasma concentrations of IL-1β, tumour necrosis factor-α, IL-12p70, IL-17A, and IL-23 were significantly elevated in the scar group (all P < 0.05). Gene expression analysis identified persistent upregulation of nuclear factor kappa B1 (NFκB1; 2.21-fold) and IL-17 (3.38-fold).
CONCLUSION: Paediatric burn survivors with hypertrophic scarring demonstrate persistent systemic immune dysregulation several years after injury. However, the cross-sectional design and absence of a normotrophic burn control group limit conclusions regarding whether these immune alterations are specific to pathological scarring or reflect broader long-term post-burn immune dysregulation.
METHODS: Peripheral blood mononuclear cells and plasma were analysed from 20 paediatric participants: 10 burn survivors with hypertrophic scarring (median 4.1 years post-injury) and 10 age- and sex-matched healthy controls. Multiparameter flow cytometry, multiplex cytokine analysis, and quantitative reverse-transcription polymerase chain reaction (qRT-PCR) were used to assess immune cell phenotypes, inflammatory mediators, and inflammatory gene expression.
RESULTS: Overall proportions of major immune cell subsets were comparable between groups. However, burn survivors with hypertrophic scarring demonstrated increased CD4⁺TNFα⁺ cells, Th17 cells, CCR6⁺ natural killer T-like cells, IL-23⁺ natural killer cells, and IL-23-expressing macrophage populations (all P < 0.05). Regulatory T cells (Tregs) and CCR4⁺CCR6⁺ double-positive Tregs were also increased (P < 0.05). Plasma concentrations of IL-1β, tumour necrosis factor-α, IL-12p70, IL-17A, and IL-23 were significantly elevated in the scar group (all P < 0.05). Gene expression analysis identified persistent upregulation of nuclear factor kappa B1 (NFκB1; 2.21-fold) and IL-17 (3.38-fold).
CONCLUSION: Paediatric burn survivors with hypertrophic scarring demonstrate persistent systemic immune dysregulation several years after injury. However, the cross-sectional design and absence of a normotrophic burn control group limit conclusions regarding whether these immune alterations are specific to pathological scarring or reflect broader long-term post-burn immune dysregulation.
Предметные рубрики MeSH
HumansBurnsFemaleMaleChildInflammationCytokinesCicatrix, HypertrophicChild, PreschoolKiller Cells, NaturalT-Lymphocytes, RegulatoryAdolescentTh17 CellsCase-Control StudiesMacrophagesTumor Necrosis Factor-alphaReceptors, CCR6Flow CytometryInterleukin-23Interleukin-1betaInterleukin-17Receptors, CCR4Chronic Disease